By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


BioTime, Inc. 

1301 Harbor Bay Parkway

Alameda  California  94502  U.S.A.
Phone: 510-521-3390 Fax: 510-521-3389


Company News
BioTime (BTX)'s Subsidiary OncoCyte Corporation's CEO Dr. Joseph Wagner To Present At BTIG’s Inaugural “Emerging Technologies In Healthcare Diagnostics” Symposium 9/19/2014 8:28:40 AM
BioTime (BTX) Announces Presentation Of Phase 3 Data At EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 9/19/2014 7:23:10 AM
BioTime (BTX)’s Subsidiary Cell Cure Neurosciences Ltd. Demonstrates The Safety And Efficacy Of Opregen® In Preclinical Animal Studies 9/17/2014 11:02:24 AM
BioTime (BTX)'s Subsidiary OncoCyte Corporation And Abcodia To Collaborate On Breast Cancer Diagnostic Development 9/15/2014 11:00:54 AM
BioTime (BTX) CEO Dr. Michael D. West To Present At Rodman & Renshaw 16th Annual Healthcare Conference 9/9/2014 9:40:49 AM
Asterias Biotherapeutics Announces Record Date For Distribution Of BioTime (BTX) Warrants To Holders Of Asterias Series A Common Stock 9/8/2014 9:17:49 AM
BioTime (BTX) To Collaborate With The University of Wisconsin And Louvain University In Test Of Hystem®-Based Hydrogel For Vocal Fold Scarring 8/28/2014 10:23:31 AM
BioTime (BTX) Subsidiary Asterias Biotherapeutics Receives FDA Clearance To Initiate Phase 1/2a Clinical Trial Of AST-OPC1 In Patients With Cervical Complete Spinal Cord Injury 8/27/2014 10:56:06 AM
BioTime (BTX) Announces Second Quarter 2014 Results And Recent Developments 8/12/2014 8:43:59 AM
BioTime (BTX) Receives FDA Premarket Notification Clearance For Premvia™ 510(k) 8/12/2014 8:22:38 AM